Smithbridge Asset Management Inc. DE Trims Stake in Thermo Fisher Scientific Inc. $TMO

Smithbridge Asset Management Inc. DE lowered its stake in Thermo Fisher Scientific Inc. (NYSE:TMO) by 4.9% during the second quarter, according to the company in its most recent filing with the SEC. The institutional investor owned 8,764 shares of the medical research company’s stock after selling 449 shares during the quarter. Smithbridge Asset Management Inc. DE’s holdings in Thermo Fisher Scientific were worth $3,553,000 as of its most recent filing with the SEC.

A number of other institutional investors and hedge funds have also recently bought and sold shares of the stock. Nordea Investment Management AB lifted its stake in Thermo Fisher Scientific by 5.9% in the 2nd quarter. Nordea Investment Management AB now owns 63,191 shares of the medical research company’s stock valued at $25,979,000 after buying an additional 3,512 shares in the last quarter. Commons Capital LLC raised its holdings in Thermo Fisher Scientific by 6.1% in the 2nd quarter. Commons Capital LLC now owns 2,655 shares of the medical research company’s stock valued at $1,076,000 after acquiring an additional 153 shares during the last quarter. S Bank Fund Management Ltd raised its holdings in Thermo Fisher Scientific by 22.9% in the 2nd quarter. S Bank Fund Management Ltd now owns 23,751 shares of the medical research company’s stock valued at $9,630,000 after acquiring an additional 4,429 shares during the last quarter. Harbor Asset Planning Inc. acquired a new position in Thermo Fisher Scientific in the 2nd quarter valued at $34,000. Finally, Bellecapital International Ltd. raised its holdings in Thermo Fisher Scientific by 11.1% in the 2nd quarter. Bellecapital International Ltd. now owns 14,496 shares of the medical research company’s stock valued at $5,878,000 after acquiring an additional 1,443 shares during the last quarter. Hedge funds and other institutional investors own 89.23% of the company’s stock.

Thermo Fisher Scientific Stock Performance

NYSE:TMO opened at $536.75 on Friday. The company has a debt-to-equity ratio of 0.65, a current ratio of 1.93 and a quick ratio of 1.50. The firm has a 50-day moving average of $494.18 and a two-hundred day moving average of $449.02. The stock has a market cap of $202.68 billion, a P/E ratio of 31.04, a PEG ratio of 2.87 and a beta of 0.77. Thermo Fisher Scientific Inc. has a 1-year low of $385.46 and a 1-year high of $610.97.

Thermo Fisher Scientific (NYSE:TMO) last posted its quarterly earnings data on Wednesday, July 23rd. The medical research company reported $5.36 earnings per share for the quarter, beating analysts’ consensus estimates of $5.22 by $0.14. The company had revenue of $10.86 billion during the quarter, compared to analysts’ expectations of $10.68 billion. Thermo Fisher Scientific had a net margin of 15.24% and a return on equity of 16.82%. The firm’s revenue for the quarter was up 2.9% on a year-over-year basis. During the same period in the prior year, the company posted $5.37 EPS. Thermo Fisher Scientific has set its Q3 2025 guidance at 5.460-5.510 EPS. FY 2025 guidance at 22.220-22.840 EPS. On average, research analysts expect that Thermo Fisher Scientific Inc. will post 23.28 earnings per share for the current fiscal year.

Insider Transactions at Thermo Fisher Scientific

In other news, EVP Gianluca Pettiti sold 400 shares of the stock in a transaction dated Friday, July 25th. The shares were sold at an average price of $479.98, for a total transaction of $191,992.00. Following the transaction, the executive vice president owned 22,367 shares of the company’s stock, valued at approximately $10,735,712.66. This trade represents a 1.76% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, CEO Marc N. Casper sold 10,000 shares of the stock in a transaction dated Friday, August 22nd. The stock was sold at an average price of $500.96, for a total transaction of $5,009,600.00. Following the transaction, the chief executive officer directly owned 115,174 shares in the company, valued at $57,697,567.04. The trade was a 7.99% decrease in their position. The disclosure for this sale can be found here. Over the last 90 days, insiders have sold 30,066 shares of company stock valued at $14,182,963. Insiders own 0.33% of the company’s stock.

Wall Street Analysts Forecast Growth

Several brokerages have weighed in on TMO. Barclays boosted their price target on Thermo Fisher Scientific from $550.00 to $585.00 and gave the company an “overweight” rating in a report on Thursday, October 2nd. Evercore ISI upped their price objective on Thermo Fisher Scientific from $525.00 to $590.00 and gave the stock an “outperform” rating in a report on Tuesday, October 7th. William Blair began coverage on Thermo Fisher Scientific in a report on Monday, August 18th. They set an “outperform” rating for the company. Weiss Ratings reiterated a “hold (c)” rating on shares of Thermo Fisher Scientific in a report on Tuesday. Finally, Royal Bank Of Canada set a $561.00 price target on Thermo Fisher Scientific and gave the company an “outperform” rating in a report on Tuesday, September 2nd. Fifteen analysts have rated the stock with a Buy rating and six have issued a Hold rating to the company’s stock. According to MarketBeat.com, Thermo Fisher Scientific has a consensus rating of “Moderate Buy” and an average target price of $589.10.

Thermo Fisher Scientific Company Profile

Thermo Fisher Scientific Inc provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the North America, Europe, Asia-Pacific, and internationally. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases; and solutions include biosciences, genetic sciences, and bio production to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets.